rs80359024
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM1PM2PP3_ModeratePP5
The NM_000059.4(BRCA2):c.7964A>G(p.Gln2655Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,461,846 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Q2655H) has been classified as Uncertain significance.
Frequency
Consequence
NM_000059.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BRCA2 | NM_000059.4 | c.7964A>G | p.Gln2655Arg | missense_variant | 17/27 | ENST00000380152.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.7964A>G | p.Gln2655Arg | missense_variant | 17/27 | 5 | NM_000059.4 | A2 |
Frequencies
GnomAD3 genomes ? Cov.: 32
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461846Hom.: 0 Cov.: 33 AF XY: 0.00000138 AC XY: 1AN XY: 727222
GnomAD4 genome ? Cov.: 32
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:3Uncertain:2
Uncertain significance, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA2) | Dec 23, 2003 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jan 10, 2024 | This missense variant replaces glutamine with arginine at codon 2655 of the BRCA2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). A functional study reported that this variant impacts BRCA2 function in a homology-mediated repair assay (PMID: 29394989). This variant has been detected in two individuals affected with breast cancer and absent in 53461 unaffected individuals in a breast cancer case-control meta-analysis (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA2_000247). This variant also has been found in trans with a pathogenic truncation variant in BRCA2 in an individual diagnosed with Fanconi anemia (PMID: 20608899). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Sep 06, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Aug 31, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
not provided Pathogenic:4
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 25, 2023 | Observed in individuals undergoing multi-gene panel testing based on a personal and/or family history of cancer, as well as in individuals with breast cancer in a case-control study (Li et al., 2020; Dorling et al., 2021); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Published functional studies demonstrate decreased homology directed repair activity (Guidugli et al., 2018; Hart et al., 2019; Iversen et al., 2022); Also known as c.8192A>G; This variant is associated with the following publications: (PMID: 19043619, 26064523, 11430722, 29394989, 29884841, 35665744, 31131967, 29158857, 31853058, 32377563, 12228710, 33471991, 20608899) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Dec 15, 2022 | PP4, PM2, PS2, PS3_moderate - |
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Feb 17, 2021 | This variant has been reported with another pathogenic BRCA2 variant in trans (on a different chromosome) in an individual affected with Fanconi Anemia (PMIDs: 11430722 (2001) and 20608899 (2010)). In addition, this variant was reported to have a damaging effect on homology-directed repair in a peer-reviewed experimental study (PMID: 29394989 (2018)). This variant has not been reported in large, multi-ethnic general populations. Variant is predicted to have a damaging effect on the protein and is located in a potentially critical domain of the protein. Based on the available information, this variant is classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | May 10, 2019 | - - |
Familial cancer of breast Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jun 30, 2023 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Feb 12, 2024 | Criteria applied: PS3,PM3,PM2_SUP - |
Hereditary cancer-predisposing syndrome Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Mar 29, 2023 | This missense variant replaces glutamine with arginine at codon 2655 of the BRCA2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). A functional study reported that this variant impacts BRCA2 function in a homology-mediated repair assay (PMID: 29394989). This variant has been detected in two individuals affected with breast cancer and absent in 53461 unaffected individuals in a breast cancer case-control meta-analysis (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA2_000247). This variant also has been found in trans with a pathogenic truncation variant in BRCA2 in an individual diagnosed with Fanconi anemia (PMID: 20608899). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 06, 2023 | The p.Q2655R pathogenic mutation (also known as c.7964A>G), located in coding exon 16 of the BRCA2 gene, results from an A to G substitution at nucleotide position 7964. The glutamine at codon 2655 is replaced by arginine, an amino acid with highly similar properties. This alteration was detected in trans with a BRCA2 pathogenic nonsense mutation in an archived medulloblastoma sample from a deceased girl with Fanconi Anemia (Ruud E et al. Acta Paediatr. 2001 May;90:580-3; Bodd TL et al. Acta Paediatr. 2010 Nov;99:1741-3). This alteration is also defective in a homology directed DNA repair (HDR) assay (Guidugli L et al. Am. J. Hum. Genet. 2018 02;102(2):233-248). Based on internal structural analysis this alteration is likely to disrupt DSS1 binding and is predicted to be as destabilizing to the local structure as other known pathogenic variants (Yang H et al. Science 2002 Sep;297:1837-48; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this alteration is interpreted as a disease-causing mutation. However, because this variant is identified in one or more patients with Fanconi Anemia it may be hypomorphic and thus, carriers of this variant and their families may present with reduced risks, and not with the typical clinical characteristics of a high-risk pathogenic BRCA2 alteration. As risk estimates are unknown at this time, clinical correlation is advised. - |
Hereditary breast ovarian cancer syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Invitae | Dec 27, 2023 | This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 2655 of the BRCA2 protein (p.Gln2655Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Fanconi anemia (PMID: 20608899). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This missense change has been observed to co-occur in individuals with a different variant in BRCA2 that has been determined to be pathogenic (Invitae), but the significance of this finding is unclear. ClinVar contains an entry for this variant (Variation ID: 52450). An algorithm developed specifically for the BRCA2 gene suggests that this missense change is likely to be deleterious (Invitae). Experimental studies have shown that this missense change affects BRCA2 function (PMID: 29394989, 29884841). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at